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Post-approval	 changes	 are	 inevitable	 and	 necessary	 throughout	 the	 lifecycle	 of	
pharmaceutical	 products	 to	 implement	 new	 knowledge,	 maintain	 a	 state	 of	 control,	 and	
drive	continual	improvement.		
This	One-Voice-of-Quality	 (1VQ)	position	paper	 is	part	of	 a	 series	of	 industry	 case	 studies	
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Furthermore,	 this	 1VQ	 position	 paper	 provides	 a	 practical	 application	 of	 the	 concepts	
described	in	ICH	Q9,	Quality	Risk	Management	[2],	ICH	Q10,	Pharmaceutical	Quality	System	
[3],	 and	 ICH	 Q12,	 Technical	 and	 Regulatory	 Considerations	 for	 Pharmaceutical	 Product	
Lifecycle	 Management	 [4]	 to	 changes	 to	 analytical	 equipment/instrumentation	 that	 are	
deemed	to	be	equivalent.			
This	paper	describes	changes	 to	analytical	equipment	 that	are	considered	 ‘like	 for	 like’	or	






CMC,	 Chemistry	Manufacturing	 and	 Control,	 Regulatory,	 Post-approval	 Change,	 PAC,	 ICH	
Q9,	 Quality	 Risk	 Management,	 QRM,	 ICH	 Q10,	 Pharmaceutical	 Quality	 System,	 PQS,	 ICH	
Q12,	 Lifecycle	 Management,	 Change	 Control,	 Regulatory	 Considerations,	 Regulatory	







ICH	 Q10,	 Pharmaceutical	 Quality	 System,	 Annex	 1	 describes	 potential	 opportunities	 to	
enhance	science	and	risk-based	regulatory	approaches	to	PACs	as	follows:	When	a	company	
can	 “demonstrate	 effective	 PQS	 and	 product	 and	 process	 understanding”	 this	 is	 an	
opportunity	 to	 “optimize	 science	 and	 risk-based	 PAC	processes	 to	maximize	 benefits	 from	
innovation	and	 continual	 improvement”	 [3].	 Current	 regulatory	mechanisms	and	guidance	
for	 PACs	 do	 not	 consider	 the	 company’s	 latest	 product	 and	 process	 knowledge	 when	
determining	the	type	of	filing	required	to	implement	the	change.	Further,	the	application	of	
ICH	Q9,	Quality	Risk	Management,	 or	 the	effectiveness	of	 the	 company’s	PQS	 to	manage	
PACs	 is	 not	 considered	 during	 the	 assessment	 of	 individual	 PACs	 or	 during	 inspections.	
Demonstrating	 a	 detailed	 understanding,	 effective	 implementation,	 and	 compliance	 with	
ICH	 Q10,	 will	 allow	 companies	 to	 overcome	 barriers	 to	 continual	 improvement	 and	




to	 be	 equivalent	 demonstrates	 the	 application	 of	 the	 principles	 outlined	 in	 ICH	Q9,	 Q10,	
Q12	irrespective	of	current	national	or	regional	reporting	category,	and	concludes	that	such	
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with	 the	 associated	 operating	 parameters	 relevant	 for	 that	 equipment/instrument/part	
within	 the	 registrations.	 Often	 an	 allowance	 is	 included	 for	 an	 ‘equivalent’	
equipment/instrument/part	 in	 the	 registration	which	 provides	 the	 appropriate	 regulatory	
flexibility	 for	 these	 types	 of	 changes.	 However,	 there	 are	 instances,	 where	 the	 term	
“equivalent’	may	 not	 be	 included	 and	 this	 often	 creates	 an	 unnecessary	 need	 for	 health	
authority	approvals	for	these	registration	changes.		This	in	turn	delays	proactive	and	timely	
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the	 following	 types	 of	 analytical	 equipment	 changes	 so	 that	 such	 changes	 can	 be	
implemented	proactively	utilizing	the	framework	of	an	effective	PQS,	and	without	extensive	
regulatory	burden:			
• Retirement,	 de-commissioning	 or	 replacement	 of	 ‘like	 for	 like’ 1 	laboratory	











INDUSTRY	 1VQ	 POSTION	 FOR	 MANAGING	 ANALYTICAL	 CHANGES	 TO	
EQUIPMENT/INSTRUMENTATION	
	
ICH	 Q12,	 Technical	 and	 Regulatory	 Considerations	 for	 Pharmaceutical	 Product	 Lifecycle	




1 The term ‘Like for like’ applies where its replacement, retirement or decommissioning does 
not cause any change in analytical methodology, method principles, method parameters and 
method validation as defined by ICH Q2(R1), analytical specifications, or system suitability, 
and/or where full method re-validation is not required, and equivalency has been 
demonstrated.	
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for	 like’	 changes	 to	 analytical	 equipment/instrumentation,	 where	 the	 change	 can	 be	
managed	solely	within	the	PQS	as	long	as	the	change	assessment	and/or	equivalency	data	
conclude	 that	 the	 change	 does	 not	 impact	 product	 quality	 and/or	 patient	 safety.		
Instrumentation	change	types	should	be	considered	Non-Regulatory	Impacting	if	there	are	
no	changes	in	analytical	methodology,	method	principles,	method	parameters	and	method	




as	 regulatory	 impacting,	 simply	 because	 the	M3	 dossier	 has	 additional	 equipment	 details	
(e.g.	part	numbers,	brand	name,	model	or	version	numbers),	or	has	not	specifically	stated	
an	 allowance	 for	 ‘equivalent’	 equipment/instrumentation.	 There	 is	 no	 regulatory	
requirement	 to	 register	 detailed	 instrument	 settings	 and	 operating	 information,	 model	
number,	 instrument	name,	etc.;	 therefore,	 it	 is	 not	 considered	appropriate	 to	update	 the	
dossier	 with	 similar	 detail.	 These	 details	 can	 be	 removed	 or	 revised	 to	 include	 the	 term	
“equivalent”	in	future	updates	to	the	dossier.			
This	 will	 facilitate	 timely	 upgrades	 and	 replacement	 of	 outdated	 or	 aging	 analytical	
equipment,	 reducing	 related	 errors,	 issues,	 delays	 in	 testing	 and	 release	 of	 product	
ultimately	ensuring	reliable	supply.	 In	addition,	 it	will	 contribute	 towards	meeting	 the	 ICH	
Q10	 objectives	 of	 achieving	 product	 realization,	 establishing	 and	 maintaining	 a	 state	 of	
control,	and	continual	improvement.	
As	 part	 of	 a	 company’s	 change	 control	 process,	 a	 science	 and	 risk-based	 approach	 with	






Figure	1	below	 [1]	describes	 the	 risk-based	approach	 for	 assessment	of	 a	PAC	 to	 ‘like	 for	
like’	 analytical	 equipment/instrumentation.	 Application	 of	 this	 risk-based	 assessment	 and	
5
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into	 the	 change	 management	 system,	 the	 potential	 Quality,	 Safety	 Efficacy	 (QSE)	 and	
legal/regulatory	 impact	 of	 the	 change	 should	 be	 considered	 including	 current	 control	
strategies.	The	impact	assessment	indicates	that	
• there	 is	 no	 change	 in	 analytical	 methodology,	 method	 principles,	 method	






to	 the	 specific	 equipment	 details	 in	 the	 dossier,	 but	 none	 of	 these	 impact	 product	 QSE.	
Therefore,	an	update	to	the	dossier	can	be	bundled	with	a	future	change,	and	a	filing	does	
June 2019
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with	 the	 supporting	equivalency	assessment	 and	 revisions	 to	 relevant	procedures,	 can	be	
managed	solely	within	the	company’s	PQS	and	implemented	immediately	without	the	need	
for	 a	 regulatory	 submission.	 Change	 implementation,	 review	 and	 closure	 should	 be	
performed	 according	 to	 the	 change	 management	 process.	 After	 implementation	 of	 the	
change,	 any	 unintended	 consequences	 introduced	 as	 a	 result	 of	 the	 change	 should	 be	
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framework	 of	 an	 effective	 PQS,	 that	 can	 be	 utilized	 by	 any	 company	 to	 gain	 regulatory	
flexibility,	 reduce	 the	burden	and	global	 complexity,	 and	enable	 faster	 implementation	of	


















Many	 post-approval	 changes	 require	 regulatory	 agency	 approval	 by	 individual	 countries	
before	 implementation.	 Because	 of	 the	 global	 regulatory	 complexity,	 individual	 post-
approval	 changes	 (PACs)	 usually	 take	 years	 for	 full	 worldwide	 approval	 even	 when	 they	
reduce	 patient	 risk,	 improve	 compliance,	 or	 enhance	 the	 manufacturing	 process	 or	 test	
methods.		
Senior	 Quality	 leaders	 (Chief	 Quality	 Officers	 and	 Heads	 of	 Quality)	 from	 more	 than	 20	










concludes	 that	 these	 should	 be	 downgraded	 to	 a	 notification	 or	 handled	 only	 in	 the	
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